Controlling drug-to-antibody ratio and scalable reactors are key to reliable antibody-drug conjugate manufacturing success.

A recent experimental treatment may offer a new method to prevent HIV infection: by combining two antiviral tactics into a single antibody. In laboratory studies, the new molecule forced the virus to ...

TOKYO, March 12, 2026 3 FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announces its investment in ...

AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ /6821.HK), recently announced that its Fengxian commercial ...

The Monoclonal Antibodies Market has emerged as one of the most transformative sectors within the global biopharmaceutical ...

The Contract Development and Manufacturing Organization (CDMO) industry in India is a fast-growing segment of the pharmaceutical sector that provides outsourced drug development and manufacturing ...

Non-CHO cell expression systems gain traction as faster, more flexible alternatives for biologics manufacturing.

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...

BioNTech’s CEO and his fellow co-founder will depart the biopharma by the end of the year to head up a new company focused on “next generation mRNA innovations.” Uğur Şahin, M.D., who is currently the ...

The data flowing through our hiring platform reveals a market that is no longer just ‘hiring for headcount’—it is hiring for pipeline certainty.

FDA's elevated meeting status signals transition from biomarker data discussions to Accelerated Approval discussions OS ...